UNSPSC 51342002: Disoxaril

This classification denotes an antiviral agent with the molecular formula C20H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FX8Q9PI4VP, chemically known as 5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methylisoxazole but generally known as disoxaril, which bears US NIH Compound Identifier 55717. European Medicines Agency schedules Disoxaril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06322MIG.

UNSPSC 51342002 Disoxaril, a Commodity code, shows limited recent state and local procurement activity aligned directly to its scope. The one relevant opportunity on record involves pharmaceutical supply through a cooperative purchasing vehicle, though the sourced records include a naloxone procurement that falls outside the code's nominal pharmaceutical focus. State and local governments using this code are procuring pharmaceutical products through established cooperative purchasing consortia and piggyback arrangements rather than direct solicitations. The Illinois Department of Public Health awarded a contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for a pharmaceutical warehouse piggyback arrangement totaling $2,999,999.11 over three years, though the actual products supplied (Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets) differ from the code's stated scope. This procurement type—leveraging state purchasing consortium frameworks—appears to be the dominant sourcing model for products in this category.

Activity is concentrated in the Midwest and Southeast, with Illinois and Florida showing the most recent procurement records. The Illinois Department of Public Health contract represents established health-department purchasing through cooperative vehicles, a pattern common among state health agencies managing pharmaceutical inventory. The Seminole County, Florida opportunity posted June 30, 2026, with a response date of July 26, 2026, procured naloxone and drug deactivation systems through a county IFB process, indicating county-level health and emergency-services demand as well, though this particular procurement sits outside the disoxaril code's direct scope. Buyers in this category appear to favor structured cooperative purchasing and piggyback frameworks over open competitive bidding for routine pharmaceutical supply.